Published in Proc Natl Acad Sci U S A on April 08, 2013
Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer. Mol Syst Biol (2014) 1.21
Functional gold nanoparticles as potent antimicrobial agents against multi-drug-resistant bacteria. ACS Nano (2014) 1.05
MiR-101 suppresses the epithelial-to-mesenchymal transition by targeting ZEB1 and ZEB2 in ovarian carcinoma. Oncol Rep (2014) 0.98
Epithelial-mesenchymal transition: a new target in anticancer drug discovery. Nat Rev Drug Discov (2016) 0.98
Cuprous oxide nanoparticles inhibit the growth and metastasis of melanoma by targeting mitochondria. Cell Death Dis (2013) 0.85
Sensitization of ovarian cancer cells to cisplatin by gold nanoparticles. Oncotarget (2014) 0.84
Differential cytotoxic and radiosensitizing effects of silver nanoparticles on triple-negative breast cancer and non-triple-negative breast cells. Int J Nanomedicine (2015) 0.84
The energy blocker inside the power house: Mitochondria targeted delivery of 3-bromopyruvate. Chem Sci (2015) 0.80
Understanding protein-nanoparticle interaction: a new gateway to disease therapeutics. Bioconjug Chem (2014) 0.80
Poly(styrene)-b-poly(DL-lactide) copolymer-based nanoparticles for anticancer drug delivery. Int J Nanomedicine (2014) 0.78
Role of cystathionine beta synthase in lipid metabolism in ovarian cancer. Oncotarget (2015) 0.77
Nuclear Membrane-Targeted Gold Nanoparticles Inhibit Cancer Cell Migration and Invasion. ACS Nano (2017) 0.76
Convergence of nanotechnology and cancer prevention: are we there yet? Cancer Prev Res (Phila) (2014) 0.75
The Histochemistry and Cell Biology compendium: a review of 2012. Histochem Cell Biol (2013) 0.75
Gold nanoparticles enhance TRAIL sensitivity through Drp1-mediated apoptotic and autophagic mitochondrial fission in NSCLC cells. Int J Nanomedicine (2017) 0.75
Interaction of gold nanoparticles with proteins and cells. Sci Technol Adv Mater (2015) 0.75
Current challenges towards in vitro cellular validation of inorganic nanoparticles. Bioconjug Chem (2016) 0.75
Silver nanoparticles outperform gold nanoparticles in radiosensitizing U251 cells in vitro and in an intracranial mouse model of glioma. Int J Nanomedicine (2016) 0.75
Exploring gold nanoparticle interactions with proteins and the tumor microenvironment in biological systems. Transl Cancer Res (2017) 0.75
Targeting cancer cell integrins using gold nanorods in photothermal therapy inhibits migration through affecting cytoskeletal proteins. Proc Natl Acad Sci U S A (2017) 0.75
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
MicroRNAs: target recognition and regulatory functions. Cell (2009) 92.17
Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc (2008) 62.52
Epithelial-mesenchymal transitions in development and disease. Cell (2009) 39.17
Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet (2008) 32.08
Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science (2005) 23.44
Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol (2006) 23.04
Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science (2009) 18.40
TGFbeta in Cancer. Cell (2008) 17.44
BRAF mutation predicts sensitivity to MEK inhibition. Nature (2005) 17.14
The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol (2006) 11.16
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene (2010) 9.66
Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer (2009) 9.33
Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer (2003) 8.35
Gold nanoparticles: a new X-ray contrast agent. Br J Radiol (2006) 6.31
Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3' kinase/AKT pathways. Oncogene (2005) 5.50
Ovarian cancer. Lancet (2009) 3.95
Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol (2008) 3.68
Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta (2009) 3.55
Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer (2009) 3.46
EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell (2002) 3.21
Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell (2012) 3.19
Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Oncol (2007) 2.98
ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Res (2003) 2.75
Activation of the Erk pathway is required for TGF-beta1-induced EMT in vitro. Neoplasia (2004) 2.60
Hepatocyte growth factor induces cell scattering through MAPK/Egr-1-mediated upregulation of Snail. EMBO J (2006) 2.38
Biological properties of "naked" metal nanoparticles. Adv Drug Deliv Rev (2008) 2.33
EMT as the ultimate survival mechanism of cancer cells. Semin Cancer Biol (2012) 2.22
Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent. Cancer Res (2008) 2.20
Lysosomal targeting of E-cadherin: a unique mechanism for the down-regulation of cell-cell adhesion during epithelial to mesenchymal transitions. Mol Cell Biol (2005) 2.19
Targeting the TGF beta signaling network in human neoplasia. Cancer Cell (2003) 2.16
E-cadherin induces mesenchymal-to-epithelial transition in human ovarian surface epithelium. Proc Natl Acad Sci U S A (1999) 2.05
Nanoconjugation modulates the trafficking and mechanism of antibody induced receptor endocytosis. Proc Natl Acad Sci U S A (2010) 1.95
USP15 stabilizes TGF-β receptor I and promotes oncogenesis through the activation of TGF-β signaling in glioblastoma. Nat Med (2012) 1.93
Antiangiogenic properties of gold nanoparticles. Clin Cancer Res (2005) 1.78
Effect of nanoparticle surface charge at the plasma membrane and beyond. Nano Lett (2010) 1.77
Integration of TGF-beta and Ras/MAPK signaling through p53 phosphorylation. Science (2007) 1.65
Inhibition of FAK signaling activated by urokinase receptor induces dormancy in human carcinoma cells in vivo. Oncogene (2002) 1.65
Intrinsic therapeutic applications of noble metal nanoparticles: past, present and future. Chem Soc Rev (2012) 1.55
Epithelial-to-mesenchymal transition in prostate cancer: paradigm or puzzle? Nat Rev Urol (2011) 1.53
Epithelial-to-mesenchymal transition and ovarian tumor progression induced by tissue transglutaminase. Cancer Res (2009) 1.39
Role of hedgehog signaling in ovarian cancer. Clin Cancer Res (2008) 1.36
Activation of cancer-specific gene expression by the survivin promoter. J Natl Cancer Inst (2002) 1.35
E-cadherin inhibits cell surface localization of the pro-migratory 5T4 oncofetal antigen in mouse embryonic stem cells. Mol Biol Cell (2007) 1.26
Angiogenesis in epithelian ovarian cancer. Mol Pathol (2002) 1.21
Angiogenesis in normal and neoplastic ovaries. Angiogenesis (2005) 1.16
Mechanism of anti-angiogenic property of gold nanoparticles: role of nanoparticle size and surface charge. Nanomedicine (2011) 1.02
Estrogen-related receptor gamma promotes mesenchymal-to-epithelial transition and suppresses breast tumor growth. Cancer Res (2011) 0.96
Modulation of angiogenic phenotype alters tumorigenicity in rat ovarian epithelial cells. Cancer Res (2007) 0.96
TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients. BMC Cancer (2010) 0.88
Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles. Circulation (2003) 3.68
Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res (2003) 2.70
Endothelial alpha(v)beta3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arterioscler Thromb Vasc Biol (2006) 2.45
Biological properties of "naked" metal nanoparticles. Adv Drug Deliv Rev (2008) 2.33
Molecular MR imaging of melanoma angiogenesis with alphanubeta3-targeted paramagnetic nanoparticles. Magn Reson Med (2005) 2.30
Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent. Cancer Res (2008) 2.20
Nanoconjugation modulates the trafficking and mechanism of antibody induced receptor endocytosis. Proc Natl Acad Sci U S A (2010) 1.95
Targeted nanoparticles for quantitative imaging of sparse molecular epitopes with MRI. Magn Reson Med (2004) 1.83
The use of microorganisms for the formation of metal nanoparticles and their application. Appl Microbiol Biotechnol (2005) 1.81
Antiangiogenic properties of gold nanoparticles. Clin Cancer Res (2005) 1.78
Effect of nanoparticle surface charge at the plasma membrane and beyond. Nano Lett (2010) 1.77
Laminin receptor specific therapeutic gold nanoparticles (198AuNP-EGCg) show efficacy in treating prostate cancer. Proc Natl Acad Sci U S A (2012) 1.72
Quantitative "magnetic resonance immunohistochemistry" with ligand-targeted (19)F nanoparticles. Magn Reson Med (2004) 1.68
MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancer. Cancer Res (2009) 1.64
Noninvasive radiofrequency field-induced hyperthermic cytotoxicity in human cancer cells using cetuximab-targeted gold nanoparticles. J Exp Ther Oncol (2008) 1.59
Intracellular gold nanoparticles enhance non-invasive radiofrequency thermal destruction of human gastrointestinal cancer cells. J Nanobiotechnology (2008) 1.56
Endothelial cell-specific chemotaxis receptor (ecscr) promotes angioblast migration during vasculogenesis and enhances VEGF receptor sensitivity. Blood (2010) 1.55
Intrinsic therapeutic applications of noble metal nanoparticles: past, present and future. Chem Soc Rev (2012) 1.55
Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer. Adv Drug Deliv Rev (2009) 1.54
Modulating pharmacokinetics, tumor uptake and biodistribution by engineered nanoparticles. PLoS One (2011) 1.53
Revealing the role of phospholipase Cβ3 in the regulation of VEGF-induced vascular permeability. Blood (2012) 1.51
Chemically modified peptides targeting the PDZ domain of GIPC as a therapeutic approach for cancer. ACS Chem Biol (2012) 1.50
NHERF-2 maintains endothelial homeostasis. Blood (2012) 1.47
Three-dimensional MR mapping of angiogenesis with alpha5beta1(alpha nu beta3)-targeted theranostic nanoparticles in the MDA-MB-435 xenograft mouse model. FASEB J (2008) 1.41
Potential therapeutic application of gold nanoparticles in B-chronic lymphocytic leukemia (BCLL): enhancing apoptosis. J Nanobiotechnology (2007) 1.37
Improved molecular imaging contrast agent for detection of human thrombus. Magn Reson Med (2003) 1.37
Regulatory role of dynamin-2 in VEGFR-2/KDR-mediated endothelial signaling. FASEB J (2005) 1.37
Association between pH-weighted endogenous amide proton chemical exchange saturation transfer MRI and tissue lactic acidosis during acute ischemic stroke. J Cereb Blood Flow Metab (2011) 1.36
Role of hedgehog signaling in ovarian cancer. Clin Cancer Res (2008) 1.36
Bombesin functionalized gold nanoparticles show in vitro and in vivo cancer receptor specificity. Proc Natl Acad Sci U S A (2010) 1.35
Gold nanoparticles: opportunities and challenges in nanomedicine. Expert Opin Drug Deliv (2010) 1.32
Effect of rapamycin alone and in combination with antiangiogenesis therapy in an orthotopic model of human pancreatic cancer. Clin Cancer Res (2004) 1.31
Inhibition of vascular permeability factor/vascular endothelial growth factor-mediated angiogenesis by the Kruppel-like factor KLF2. J Biol Chem (2005) 1.31
Enzyme mediated extracellular synthesis of CdS nanoparticles by the fungus, Fusarium oxysporum. J Am Chem Soc (2002) 1.26
Targeted PARACEST nanoparticle contrast agent for the detection of fibrin. Magn Reson Med (2006) 1.25
VEGF exerts an angiogenesis-independent function in cancer cells to promote their malignant progression. Cancer Res (2012) 1.21
Molecular imaging of human thrombus with computed tomography. Acad Radiol (2005) 1.21
Regulation of vascular endothelial growth factor receptor 2 trafficking and angiogenesis by Golgi localized t-SNARE syntaxin 6. Blood (2010) 1.21
Radioactive gold nanoparticles in cancer therapy: therapeutic efficacy studies of GA-198AuNP nanoconstruct in prostate tumor-bearing mice. Nanomedicine (2009) 1.19
Nanoparticle pharmacokinetic profiling in vivo using magnetic resonance imaging. Magn Reson Med (2008) 1.19
Fast multislice pH-weighted chemical exchange saturation transfer (CEST) MRI with Unevenly segmented RF irradiation. Magn Reson Med (2010) 1.18
Vascular endothelial growth factor-C protects prostate cancer cells from oxidative stress by the activation of mammalian target of rapamycin complex-2 and AKT-1. Cancer Res (2009) 1.15
Upregulation of VEGF-C by androgen depletion: the involvement of IGF-IR-FOXO pathway. Oncogene (2005) 1.14
Nanocompatible chemistry toward fabrication of target-specific gold nanoparticles. J Am Chem Soc (2006) 1.11
Expression and regulatory role of GAIP-interacting protein GIPC in pancreatic adenocarcinoma. Cancer Res (2006) 1.11
Src homology 2 (SH2) domain containing protein tyrosine phosphatase-1 (SHP-1) dephosphorylates VEGF Receptor-2 and attenuates endothelial DNA synthesis, but not migration*. J Mol Signal (2008) 1.11
Inorganic nanoparticles in cancer therapy. Pharm Res (2010) 1.11
Cystathionine beta-synthase (CBS) contributes to advanced ovarian cancer progression and drug resistance. PLoS One (2013) 1.10
Lysosome-related organelles in intestinal cells are a zinc storage site in C. elegans. Cell Metab (2012) 1.09
Gadolinium-modulated 19F signals from perfluorocarbon nanoparticles as a new strategy for molecular imaging. Magn Reson Med (2008) 1.09
Simulation and optimization of pulsed radio frequency irradiation scheme for chemical exchange saturation transfer (CEST) MRI-demonstration of pH-weighted pulsed-amide proton CEST MRI in an animal model of acute cerebral ischemia. Magn Reson Med (2011) 1.08
Fluorine cardiovascular magnetic resonance angiography in vivo at 1.5 T with perfluorocarbon nanoparticle contrast agents. J Cardiovasc Magn Reson (2007) 1.07
Distinct role of PLCbeta3 in VEGF-mediated directional migration and vascular sprouting. J Cell Sci (2009) 1.07
Sclerostin binds and regulates the activity of cysteine-rich protein 61. Biochem Biophys Res Commun (2009) 1.05
Mechanism of anti-angiogenic property of gold nanoparticles: role of nanoparticle size and surface charge. Nanomedicine (2011) 1.02
Enhancing chemotherapy response with Bmi-1 silencing in ovarian cancer. PLoS One (2011) 1.01
Gold coated lanthanide phosphate nanoparticles for targeted alpha generator radiotherapy. PLoS One (2013) 1.00
Protein kinase C zeta transactivates hypoxia-inducible factor alpha by promoting its association with p300 in renal cancer. Cancer Res (2004) 0.97
Use of bomb pulse carbon-14 to age senile plaques and neurofibrillary tangles in Alzheimer's disease. Neurobiol Aging (2002) 0.97
Designing nanoconjugates to effectively target pancreatic cancer cells in vitro and in vivo. PLoS One (2011) 0.96
Complexity in the vascular permeability factor/vascular endothelial growth factor (VPF/VEGF)-receptors signaling. Mol Cell Biochem (2004) 0.96
Targeting GIPC/synectin in pancreatic cancer inhibits tumor growth. Clin Cancer Res (2009) 0.96
The neurotransmitter dopamine modulates vascular permeability in the endothelium. J Mol Signal (2008) 0.96
Plumbagin inhibits tumorigenesis and angiogenesis of ovarian cancer cells in vivo. Int J Cancer (2012) 0.95
Identifying new therapeutic targets via modulation of protein corona formation by engineered nanoparticles. PLoS One (2012) 0.95
The cation diffusion facilitator gene cdf-2 mediates zinc metabolism in Caenorhabditis elegans. Genetics (2009) 0.94
In vivo toxicity studies of europium hydroxide nanorods in mice. Toxicol Appl Pharmacol (2009) 0.94
How might selenium moderate the toxic effects of mercury in stream fish of the western U.S.? Environ Sci Technol (2009) 0.93
Histidine protects against zinc and nickel toxicity in Caenorhabditis elegans. PLoS Genet (2011) 0.93
High-porosity poly(epsilon-caprolactone)/mesoporous silicon scaffolds: calcium phosphate deposition and biological response to bone precursor cells. Tissue Eng Part A (2008) 0.92
Polyethylenimine-conjugated gold nanoparticles: Gene transfer potential and low toxicity in the cornea. Nanomedicine (2011) 0.91
Dopamine regulates phosphorylation of VEGF receptor 2 by engaging Src-homology-2-domain-containing protein tyrosine phosphatase 2. J Cell Sci (2009) 0.91